A Study of ERAS-007 in Patients With Advanced Non-Small-Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
- To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination
with other cancer therapies in study participants with advanced non-small cell lung
cancer (NSCLC).
- To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007
administered in combination with other cancer therapies.
- To evaluate the antitumor activity of ERAS-007 in combination with other cancer
therapies.
- To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in
combination.